Tech Core 1

NIH RePORTER · NIH · U54 · $364,786 · view on reporter.nih.gov ↗

Abstract

Project Summary – Tech 1 The identification of key molecular and cellular events that drive the progression of metastatic breast and pancreatic cancer could lead to improved mechanistic understanding and diagnostic tools and treatments. However, the micro-anatomy of human pancreatic/breast tumors – their spatial organization and associated content in cellular and non-cellular components – is poorly understood as it is intrinsically three-dimensional, non-symmetric, and highly heterogeneous. Three-dimensional imaging tools that combine structural and spatial omic information in large volumes are required to locate these metastatic driver events in cancerous tissue. Specifically, we aim to investigate venous invasion, which is a common route of metastasis of breast and pancreatic cancer cells. In Tech1, we propose to develop a new 3D multiscale imaging method, CODA, which will allow us to probe the phenotypic heterogeneity of tumors from the multi-cm to the micron scale via multiplexing serial imaging and registration/deep-learning algorithms. Our proposed repertoire of CODA imaging methods addresses deficiencies of state-of-art tissue clearing and 3D imaging methods, including inconsistent clearing and staining, lack of validation, poor antibody penetration and limited multiplexing capabilities. CODA bypasses the limitations of optical microscopy, allowing for large volumetric imaging while achieving micron resolution regardless of the volume of the imaged tissue. Another key advantage of CODA, which is based on serially cut H&E sections, is that it can readily incorporate other imaging modalities to extract high cellular/molecular content from the 3D samples. These include immunocytochemistry (CODA+IHC), immunofluorescence (CODA+IF), and imaging mass cytometry (CODA+IMC). This is particularly important as many potential molecular and cellular contributors of intravasation/extravasation and cancer cell invasion into veins, including immune cells and cancer-associated fibroblasts, require specific labels that cannot be detected in H&E slides. These proposed expanded versions of CODA offer a unique opportunity to produce new 3D multiplex maps of human PDAC and breast tumors near and far from blood vessels. CODA and its integrated versions CODA+X will be tested in the RTB units of the Center.

Key facts

NIH application ID
10375192
Project number
1U54CA268083-01
Recipient
JOHNS HOPKINS UNIVERSITY
Principal Investigator
Pei-Hsun wu
Activity code
U54
Funding institute
NIH
Fiscal year
2022
Award amount
$364,786
Award type
1
Project period
2021-12-01 → 2026-11-30